CN101646674B - 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物 - Google Patents

用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物 Download PDF

Info

Publication number
CN101646674B
CN101646674B CN2008800102845A CN200880010284A CN101646674B CN 101646674 B CN101646674 B CN 101646674B CN 2008800102845 A CN2008800102845 A CN 2008800102845A CN 200880010284 A CN200880010284 A CN 200880010284A CN 101646674 B CN101646674 B CN 101646674B
Authority
CN
China
Prior art keywords
minutes
solvent
cyclohexyl
tfa
column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800102845A
Other languages
English (en)
Chinese (zh)
Other versions
CN101646674A (zh
Inventor
卡普-森·耶昂
约翰·F·卡道
凯瑟琳·A·格兰特-扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101646674A publication Critical patent/CN101646674A/zh
Application granted granted Critical
Publication of CN101646674B publication Critical patent/CN101646674B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2008800102845A 2007-02-02 2008-01-31 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物 Expired - Fee Related CN101646674B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US88784607P 2007-02-02 2007-02-02
US60/887,846 2007-02-02
US89488107P 2007-03-14 2007-03-14
US60/894,881 2007-03-14
US12/022,541 US7541352B2 (en) 2007-02-02 2008-01-30 Compounds for the treatment of hepatitis C
US12/022,541 2008-01-30
PCT/US2008/052573 WO2008097796A1 (en) 2007-02-02 2008-01-31 Indolobenzazepine derivatives for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
CN101646674A CN101646674A (zh) 2010-02-10
CN101646674B true CN101646674B (zh) 2013-05-29

Family

ID=39676696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800102845A Expired - Fee Related CN101646674B (zh) 2007-02-02 2008-01-31 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物

Country Status (5)

Country Link
US (1) US7541352B2 (https=)
EP (1) EP2114947B1 (https=)
JP (1) JP2010518016A (https=)
CN (1) CN101646674B (https=)
WO (1) WO2008097796A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
WO2008111978A1 (en) 2007-03-13 2008-09-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006046039A2 (en) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
WO2007033175A1 (en) * 2005-09-13 2007-03-22 Bristol-Myers Squibb Company Indolobenzazepine hcv ns5b inhibitors
WO2007143521A1 (en) * 2006-06-08 2007-12-13 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20090250T1 (hr) 2004-02-24 2009-06-30 Japan Tobacco Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
JP5205370B2 (ja) 2006-05-25 2013-06-05 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006046039A2 (en) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
WO2007033175A1 (en) * 2005-09-13 2007-03-22 Bristol-Myers Squibb Company Indolobenzazepine hcv ns5b inhibitors
WO2007143521A1 (en) * 2006-06-08 2007-12-13 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv inhibitors

Also Published As

Publication number Publication date
CN101646674A (zh) 2010-02-10
US7541352B2 (en) 2009-06-02
WO2008097796A1 (en) 2008-08-14
JP2010518016A (ja) 2010-05-27
EP2114947A1 (en) 2009-11-11
EP2114947B1 (en) 2014-01-08
US20080188458A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
CN101631790B (zh) 用于治疗丙型肝炎的化合物
CN101790533B (zh) 环丙基稠合的吲哚并苯并氮杂*hcv抑制剂
CN101730698B (zh) 用于治疗丙型肝炎的化合物
CN101679441B (zh) 用于治疗丙型肝炎的化合物
EP2209789B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101679442B (zh) 用于治疗丙型肝炎的化合物
CN101490054B (zh) 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
EP2118109B1 (en) Compounds for the treatment of hepatitis c
US8129367B2 (en) Compounds for the treatment of Hepatitis C
CN101821268B (zh) 用于治疗丙型肝炎的四环化合物
CN101918412B (zh) 用于治疗丙型肝炎的稠合有环丙基的吲哚并苯并氮杂*衍生物
EP2401280B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101646674B (zh) 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物
CN101679437B (zh) 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
CN101443336B (zh) 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130529

Termination date: 20150131

EXPY Termination of patent right or utility model